Selective serotonin reuptake inhibitors (SSRIs) prevent meta-iodobenzylguanidine (MIBG) uptake in platelets without affecting neuroblastoma tumor uptake.
Thomas BlomRutger MeinsmaMarja RutgersCorine BuitenhuisMarieke Dekken-Van den BurgAndré B P van KuilenburgGodelieve A M TytgatPublished in: EJNMMI research (2020)
Our study demonstrates for the first time that SSRIs selectively inhibit MIBG uptake in platelets without affecting MIBG accumulation in an in vivo neuroblastoma model. The concomitant application of citalopram during [131I]MIBG therapy seems a promising strategy to prevent thrombocytopenia in neuroblastoma patients.